Clinical trials: HPV Infections
Health Status Unknown, Precancerous Condition
Self-Sampling in Women Who Do Not Undergo Routine Cervical Screening
RATIONALE: Women who do not undergo routine cervical screening may be more likely to collect a self-sample for human papillomavirus testing.
- Trial name
- NCT00977392
- Testing
- compliance monitoring, cervical Papanicolaou test, educational intervention
- Where
- United Kingdom
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Barts and the London School of Medicine and Dentistry
Autoimmune Disease, Juvenile Idiopathic Arthritis
Immunogenicity of HPV Vaccine in Immunosuppressed Children
Genital HPV is the necessary cause for cervical cancer, as well as a major contributing cause of several other cancers and conditions. There are now effective vaccines against the main oncogenic HPV types, HPV16 and 18.
- Conditions
- Autoimmune Disease, Juvenile Idiopathic Arthritis, Inflammatory Bowel Disease, Evidence of Liver Transplantation
- Trial name
- NCT02263703
- Testing
- Quadrivalent HPV vaccine
- Where
- Australia
- Volunteers
- 55 people
- Sponsor
- The University of New South Wales
HIV Infection, Human Papillomavirus-Related Cervical Carcinoma
Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
Background In sub-Saharan Africa (SSA), human papillomavirus (HPV) and HIV create a dual burden of disease that causes significant morbidity and mortality in the form of cervical cancer (CC).
- Conditions
- HIV Infection, Human Papillomavirus-Related Cervical Carcinoma, Screening Strategy
- Trial name
- NCT06708351
- Testing
- Best Practice, Health Promotion and Education, HPV Self-Collection
- Where
- Kenya
- Volunteers
- 2,280 people, healthy volunteers welcome
- Sponsor
- Emory University
Infections, Papillomavirus
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
This is a multicenter study in which women are planned to receive either the HPV vaccine or control. Study participation will last approximately 72 months and involves a total of thirteen or fourteen scheduled visits.
- Trial name
- NCT00779766
- Testing
- HPV GSK 580299 vaccine
- Where
- 4 sites in China
- Volunteers
- 6,081 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Human Papilloma Virus Infection
The Parents in Appalachia Receive Education Needed for Teen Project
This clinical trial studies an educational intervention for parents and providers in increasing human papillomavirus (HPV) vaccination rates in younger girls in Ohio Appalachia.
- Trial name
- PARENT (NCT01901770)
- Testing
- educational intervention
- Where
- United States
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Condylomata Acuminata
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
The summary of this study is to know which HPV types are present in genital warts in Argentinean population.
- Trial name
- NCT01598779
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Buenos Aires
Recurrent Respiratory Papillomatosis, Papillomavirus Infection
Zopa Retreatment and Vector Shedding in Adults With RRP
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP).
- Conditions
- Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
- Trial name
- NCT06538480
- Testing
- Zopapogene imadenovec (Zopa)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Precigen, Inc
Human Papillomavirus Infection
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
This study is to evaluate the safety and tolerability profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy women ages 18-45
- Trial name
- NCT05680454
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Common Warts (Verruca Vulgaris)
Candin for the Treatment of Common Warts
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo.
- Trial name
- NCT05889845
- Testing
- Candin, Intradermal Solution
- Where
- 18 sites in United States
- Volunteers
- 330 people
- Sponsor
- Nielsen BioSciences, Inc.
Human Papilloma Virus, Atopic Asthma
Atopic Diseases & Human Papilloma Virus
Cervical cancer is an important health problem in women. Human papillomavirus (HPV) is considered the primary etiological agent of cervical cancer worldwide.
- Conditions
- Human Papilloma Virus, Atopic Asthma, Atopic Disorders
- Trial name
- NCT04397081
- Testing
- HPV test results
- Where
- Turkey (Türkiye)
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Adana Numune Training and Research Hospital
HIV Infections
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral human papillomavirus (HPV) and oral warts are common health concerns for HIV-infected people. This study will examine the frequency of oral HPV DNA shedding and oral warts in HIV-infected people who are enrolled in ACTG…
- Trial name
- NCT01029249
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
This research study is testing whether a new study drug (called ATRN-119) is safe and effective when combined with a single, highly targeted dose of radiation therapy (called stereotactic body radiation therapy or SBRT) to treat…
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, HPV Associated Cancers
- Trial name
- NCT07578467
- Testing
- ATRN-119, Stereotactic Body Radiation Therapy (SBRT)
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Anal Cancer, High-grade Squamous Intraepithelial Lesion
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL).
- Conditions
- Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
- Trial name
- ANCHOR (NCT02135419)
- Testing
- imiquimod, fluorouracil, infrared photocoagulation therapy
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 4,446 people
- Sponsor
- AIDS Malignancy Consortium
Low-Grade Intraepithelial Neoplasia of Cervix
Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection
The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.
- Trial name
- EGCG-HPV (NCT06314113)
- Testing
- Epigallocatechin Gallate
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Papillomavirus Infections, Oropharyngeal Neoplasms
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
Background: Researchers have found a new way to treat cancer. The therapy used in this study is called E7 TCR T cell therapy. This therapy is a type of treatment in which a participant s T cells (a type of immune system white…
- Trial name
- NCT04044950
- Testing
- E7 TCR
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, HPV (Human Papillomavirus)-Associated Carcinoma
Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation
The primary purpose of this research is to investigate anti-tumor immune responses in patients undergoing chemotherapy and radiation for Head and Neck Cancers.
- Conditions
- Head and Neck Cancer, HPV (Human Papillomavirus)-Associated Carcinoma, Oropharyngeal
- Trial name
- NCT01958515
- Testing
- research blood draw and tissue biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Human Papillomavirus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
- Trial name
- NCT00973362
- Testing
- APTIMA HPV Assay, FDA-Approved HPV DNA Test
- Where
- 17 sites in United States
- Volunteers
- 12,896 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
HPV Infections
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women
- Trial name
- NCT00378560
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC